UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 12, 2025

Catheter Precision, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-38677	38-3661826
(State or other jurisdiction<br><br> <br>of incorporation)	(Commission<br><br> <br>File Number)	(IRS Employer<br><br> <br>Identification No.)

1670 Highway 160 West

Suite 205

Fort Mill, SC 29708

(Address of principal executive offices, including zip code)

(973) 691-2000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	VTAK	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

Item 8.01 Other Events.

This Form 8-K is being filed for the purpose of filing the legal opinion of Arnall Golden Gregory LLP dated June 13, 2025 in connection with the Prospectus Supplement dated June 13, 2025 of Catheter Precision, Inc. (the “Company”), in order that it may be incorporated by reference into the Company’s Registration Statement on Form S-3 (Registration No. 333-284217).

Also, the Company issued a press release on June 12, 2025 regarding recent sales and sales trajectory of its LockeT product. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit	Description
5.1	Opinion Letter of Arnall Golden Gregory LLP dated June 13, 2025
99.1	Press Release Dated June 12, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CATHETER PRECISION, INC.
Date:     June 13, 2025	By:	/s/ Philip Anderson
		Philip Anderson
		Chief Financial Officer

ex_830478.htm

Exhibit 5.1

171 17th Street NW<br> Suite 2100<br> Atlanta, GA 30363<br><br> <br>Direct Phone: 404.873.8500<br><br> <br>Facsimile: 404.873.8501

June 13, 2025

Catheter Precision, Inc.

1670 Highway 160 West, Suite 205

Fort Mill, South Carolina

Ladies and Gentlemen:

We have acted as counsel to Catheter Precision, Inc., a Delaware corporation (the “Company”), in connection with the registration of the offer and sale of up to an additional $1,895,679 of shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share, pursuant to the Company’s shelf Registration Statement on Form S-3 (File No. 333-284217), filed on January 10, 2025 and declared effective by the Securities and Exchange Commission (the “Commission”) on January 22, 2025 (the “Registration Statement”).

The offering and sale of the Shares are being made pursuant to the At Market Offering Agreement (the “Sales Agreement”) dated as of May 19, 2025 by and between the Company and Ladenburg Thalmann & Co. Inc.

We have examined copies of the Sales Agreement, the Registration Statement, the base prospectus that forms a part thereof and the prospectus supplements thereto related to the offering of the Shares, including the prospectus supplement dated May 19, 2025 and the prospectus supplement dated as of the date hereof and filed by the Company in accordance with Rule 424(b) promulgated under the Securities Act of 1933, as amended. We have also examined instruments, documents and records which we deemed relevant and necessary for the basis of our opinion hereinafter expressed.

In such examination, we have assumed (i) the authenticity of original documents and the genuineness of all signatures, (ii) the conformity to the originals of all documents submitted to us as copies, and (iii) the truth, accuracy, and completeness of the information, representations and warranties contained in the records, documents, instruments and certificates we have reviewed.

Based on and subject to the foregoing, we are of the opinion that the Shares have been duly authorized by the Company and, when issued and delivered by the Company against payment therefor in accordance with the terms of the Sales Agreement, the applicable prospectus and prospectus supplements, and the Board’s authorizing resolutions, will be validly issued, fully paid and nonassessable.

We express no opinion as to the laws of any other jurisdiction other than the federal laws of the United States of America and the General Corporation Law of the State of Delaware.

We hereby consent to the filing of this opinion as an exhibit to the Company’s Current Report on Form 8-K filed on or about June 13, 2025 for incorporation by reference into the Registration Statement.

We consent to the reference to our firm under the caption “Legal Matters” in the base prospectus dated January 22, 2025 and prospectus supplement dated May 19, 2025. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

Very truly yours,<br><br> <br><br><br> <br>ARNALL GOLDEN GREGORY LLP

| www.agg.com

ex_830479.htm

Exhibit 99.1

Catheter Precision (VTAK) Anticipates Highest LockeT Sales to Date in Q2 2025

Fort Mill, SC, June 12, 2025 – Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 2025 sales are already outpacing Q2 2024 sales by more than $84,000.

Catheter Precision now has three US hospitals that are on track to issue more than $100,000 in purchase orders each for LockeT by the end 2025. These hospitals include Montefiore (Bronx, NY), Eisenhower Health (Rancho Mirage, CA), and Overland Park Regional Medical Center (Overland Park, KS).

As previously announced, LockeT received the CE Mark enabling sales in Europe. Catheter Precision has secured a new distributor in Italy and anticipates additional distributors in the coming days for Spain, Portugal and the UK and is actively searching for the right partner is other EU countries.

David Jenkins, CEO of Catheter Precision said, “We are excited about the upcoming activities, sales pipeline and expanded use by existing customer to increase revenue generated by LockeT. At this time, there is a live case scheduled on Monday, June 16 with a key opinion leader where he will demonstrate LockeT during an Italian symposium, increasing its awareness to the new market. As a company, we continue to focus on improving product awareness, increasing product usage and expanding our footprint into Europe.”

About LockeT

Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

At the Company

David Jenkins

973-691-2000

info@catheterprecision.com

#